Clinical trials: High-Risk Localized Prostate Cancer, open to volunteers
Localized Prostate Cancer
Focal Micro-boost Strategy in Patients With Intermediate- to High-risk Prostate Cancer (IR-HR PCa) Undergoing Hypofractionated Radiotherapy
HYPO62 SPECIAL is a monocentric, prospective observational cohort study promoted by IFO-IRE/ISG, designed to evaluate a moderately hypofractionated radiotherapy strategy with focal micro-boost in patients with localized…
- Trial name
- 62SPECIAL (NCT07792993)
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Regina Elena Cancer Institute
Localized Prostate Cancer, BPH (Benign Prostatic Hyperplasia)
Sonablate HIFU International Registry for PC & BPH Patients
The SONA FUSION Registry is an observational study designed to evaluate the long-term effectiveness and safety of the Sonablate High-Intensity Focused Ultrasound (HIFU) system.
- Conditions
- Localized Prostate Cancer, BPH (Benign Prostatic Hyperplasia), Prostate Cancer; Benign Prostatic Hyperplasia
- Trial name
- SONAFUSION (NCT07757490)
- Testing
- High Intensity Focused Ultrasound
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Sonablate
Prostate Cancer
Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer
This phase I trial tests the safety and feasibility of giving pasritamig before surgery in patients with unfavorable intermediate-risk, high-risk, or very high-risk localized prostate cancer.
- Trial name
- NCT07860255
- Testing
- Pasritamig
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer
Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer
This is a two-Parallel cohort, prospective study, aimed to explore Efficacy and safety of neoadjuvant Darolutamide with or without ADT in high-risk/very high-risk localized-stage prostate cancer.
- Trial name
- ANDARP (NCT07476677)
- Testing
- Darolutamide, Darolutamide combined with ADT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy
Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer
This study is for adult men with previously untreated high risk, very high risk, or pelvic lymph node positive prostate cancer. The purpose of this study is to evaluate the safety and effectiveness of the combination of two…
- Trial name
- NCT07325721
- Testing
- Hypofractionated radiation with a microboost
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Medical University of South Carolina
Prostate Cancer
PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound
The purpose of this study is to compare the sensitivity of PSMA PET/MRI and standard MRI in detecting focal therapy failure in the prostate one year after High-Intensity Focused Ultrasound (HIFU) treatment.
- Trial name
- NCT07184970
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- HYDRA (NCT04945642)
- Testing
- High-Dose Rate Brachytherapy, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer, Prostate Adenocarcinoma
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy.
- Trial name
- NCT05726292
- Testing
- Relacorilant, Enzalutamide, Androgen Deprivation Therapy
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Chicago
Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
PRO-BOOST-LC is a prospective, multicenter, randomized phase II/III clinical trial for men with localized or locally advanced prostate cancer without lymph node or distant metastases, confirmed using prostate-specific membrane…
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy, Stereotactic Body Radiation Therapy (SBRT), Dose Escalation: Solid Tumors
- Trial name
- PRO-BOOST-LC (NCT07426055)
- Testing
- Stereotactic Body Radiotherapy (SBRT) Monotherapy, External Beam Radiotherapy (EBRT) Backbone, High-Dose-Rate Brachytherapy Boost
- Where
- Poland
- Volunteers
- 1,000 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Prostate Cancer
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
The aim of this prospective, single-arm phase II study is the individualization of both radiotherapy (RT) and androgen deprivation therapy (ADT) duration for patients with high-risk localized prostate cancer (PCa) according to…
- Trial name
- HypoPro (NCT06772441)
- Testing
- Androgen deprivation therapy (ADT)
- Where
- Cyprus
- Volunteers
- 30 people
- Sponsor
- German Oncology Center, Cyprus
Male Erectile Disorder, Prostate Cancer
Focal Therapy for Prostate Cancer Using HIFU
RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men…
- Conditions
- Male Erectile Disorder, Prostate Cancer, Therapy-related Toxicity, Urinary Incontinence
- Trial name
- INDEX (NCT01194648)
- Testing
- questionnaire administration, assessment of therapy complications, high-intensity focused ultrasound ablation
- Where
- United Kingdom
- Volunteers
- 354 people
- Sponsor
- University College, London